Clinical Profile, Associated Events and Safety of Vericiguat in a Real-World Cohort: The VERITA Study
ESC Heart Failure · 2024
DOI: 10.1002/ehf2.15032 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift ESC Heart Failure, 2024. Verfasst von Mario Galván Ruiz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Hospital Universitario de Gran Canaria Doctor Negrín, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria…. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bayer.
Abstract (Originalsprache)
Aims
The aim of this study was to determine the clinical profile, associated events and safety of vericiguat in a real-world cohort of patients with heart failure with reduced ejection fraction (HFrEF).
Methods
This study is a prospective and observational cohort study of patients with HFrEF and recent HF worsening episodes requiring intravenous therapy who initiated vericiguat in an HF outpatient clinic. A subanalysis of patients with ≥6 months’ follow-up was performed separately.
Results
Out of 103 patients initially included, 52 had a follow-up of at least 6 months (median follow-up of 303 days). At baseline, the mean age was 71.3 ± 9.4 years, 27.2% were women, the median left ventricular ejection fraction was 34% (28%–39%) and 99% were taking beta-blockers, 96.1% sodium-glucose cotransporter-2 (SGLT2) inhibitors, 95.1% sacubitril–valsartan, 90.3% aldosterone antagonists and 93.2% loop diuretics. During follow-up, New York Heart Association (NYHA) functional class improved (from 67.3% and 32.7% in classes III and II, respectively, to 22.4% and 75.5% at study end; P < 0.001), as did the EuroQol-5D (EQ-5D) and visual analogue scale (VAS) scores (from 0.83 ± 0.13 to 0.87 ± 0.12, P = 0.032, and from 60 to 79, P = 0.005, respectively). Vericiguat was well tolerated (13.5% had symptomatic hypotension, and 11.5% had discontinued treatment), and 78.8% of patients achieved the target dose of 10 mg. The number of HF-related hospitalizations/decompensations within the previous 12 months was 2.3 ± 1.4 and decreased with vericiguat to 0.79 ± 1.14 (P < 0.001). At study end, 7.7% died (50% for HF).
Conclusions
In clinical practice, treatment with vericiguat is associated with substantial improvements in functional class and quality of life and a reduction in hospitalizations for HF, with a low risk of adverse effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Hospital Universitario de Gran Canaria Doctor Negrín, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
- Department of Cardiology, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain.
- Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain.
ORCID-Profile: Mario Galván Ruiz
Förderung
- Bayer
Zitieren
APA
Galván Ruiz, M., Fernández de Sanmamed Girón, M., Del Val Groba Marco, M., Rojo Jorge, L., Peña Saavedra, C., Martín Bou, E., Andrade Guerra, R., Caballero Dorta, E., & García Quintana, A. (2024). Clinical Profile, Associated Events and Safety of Vericiguat in a Real-World Cohort: The VERITA Study. ESC Heart Failure. https://doi.org/10.1002/ehf2.15032
Vancouver
Galván Ruiz M, Fernández de Sanmamed Girón M, Del Val Groba Marco M, Rojo Jorge L, Peña Saavedra C, Martín Bou E, et al. Clinical Profile, Associated Events and Safety of Vericiguat in a Real-World Cohort: The VERITA Study. ESC Heart Failure. 2024. doi:10.1002/ehf2.15032
BibTeX
@article{GalvnRuiz2024,
author = {Galván Ruiz, Mario and Fernández de Sanmamed Girón, Miguel and Del Val Groba Marco, María and Rojo Jorge, Lorena and Peña Saavedra, Claudia and Martín Bou, Elvira and Andrade Guerra, Rubén and Caballero Dorta, Eduardo and García Quintana, Antonio},
title = {Clinical Profile, Associated Events and Safety of Vericiguat in a Real-World Cohort: The VERITA Study},
journal = {ESC Heart Failure},
year = {2024},
doi = {10.1002/ehf2.15032}
}
EUVIMED